Mark Iwicki

Mr. Mark T.
Iwicki is a Chief Executive Officer & Director at Inhibikase Therapeutics, Inc., a Chairman at Q32 Bio, Inc., a Chairman at Q32 Bio Operations, Inc., a Chairman at Third Harmonic Bio, Inc. and an Advisor at Atlas Venture Advisors, Inc. He is on the Board of Directors at Inhibikase Therapeutics, Inc., Nimbus Apollo, Inc. and Pulmatrix Operating Co., Inc. Mr. Iwicki was previously employed as an Independent Director by Aerovate Therapeutics, Inc., a Chairman by Akero Therapeutics, Inc., an Independent Director by Pulmatrix, Inc., an Independent Non-Executive Director by Merus NV, an Independent Director by Aimmune Therapeutics, Inc., a Chairman by Kala Bio, Inc., a President, Chief Executive Officer & Director by Civitas Therapeutics, Inc., a President, Chief Executive Officer & Director by Blend Therapeutics, Inc., a President & Chief Executive Officer by Sunovion Pharmaceuticals, Inc., a Vice President & Head-Business Unit by Novartis Pharmaceuticals Corp., a Vice President & Head-Cardiovascular Business Unit by Novartis Pharmaceuticals UK Ltd., a Principal by Astra Merck, Inc., a Principal by Merck & Co., Inc., and a President & Chief Executive Officer by Sumitomo Pharma Co., Ltd. He also served on the board at Nimbus Therapeutics LLC, TARIS BioMedical LLC, Oxeia Biopharmaceuticals, Inc. and Wellesley Youth Hockey Association.
He received his undergraduate degree from Ball State University (Indiana) and an MBA from Loyola University Maryland, Inc..